Notice of Intent - Sole Source for Next Generation Sequencing for Illumina Reagents for HLA Typing and Organ Transplantation

The Defense Health Agency (DHA) Healthcare Contracting Division Northeast (HCD-NE) has issued a Special Notice announcing its intent to award a firm fixed price contract on a sole source basis to Illumina, Inc. The contract will support the Surgery-Organ Transplant Service Department of the Walter Reed National Military Medical Center (WRNMMC), specifically to procure Next Generation Sequencing reagents for high-resolution analysis of organ transplant donors and recipients. The notice specifically covers the MiniSeq Mid Output Kit and PhiX Control v3, which will be used with Illumina equipment. The contract will be awarded under statutory authority permitting "Other than full and Open Competition" in accordance with FAR 13.106-1(b)(1) for purchases not exceeding the Simplified Acquisition Threshold. This Special Notice is explicitly not a request for competitive proposals or quotations.

Interested contractors have until 5:00 PM EDT on Thursday, June 5, 2025, to submit their capabilities and interest via email to kendall.j.spann.civ@health.mil with a cc to fozia.a.abdulahi.civ@health.mil. The government emphasizes that any information submitted should demonstrate the offeror's capability to provide the required supplies and will be furnished at no cost or obligation. The DHA reserves sole discretion in determining whether to compete the proposed action based on responses received. The notice categorizes the procurement under NAICS 334516 (Analytical Laboratory Instrument Manufacturing) and PSC 6550 (In Vitro Diagnostic Substances, Reagents, Test Kits And Sets). Potential contractors should note that phone calls will not be accepted, and requests for solicitation copies will not be honored. The primary objective is to acquire specialized sequencing reagents critical for organ transplantation analysis.